Dupixent is the first biologic approved for chronic spontaneous urticaria in patients as young as 2 years of age. The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® ...
The FDA approved dupilumab for children aged 2 to 11 years with uncontrolled CSU—the first biologic for this pediatric population. The approval extends the indication previously approved in April 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results